Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
3(38%)
Results Posted
150%(3 trials)
Terminated
2(25%)

Phase Distribution

Ph phase_2
5
63%
Ph phase_3
2
25%

Phase Distribution

0

Early Stage

5

Mid Stage

2

Late Stage

Phase Distribution7 total trials
Phase 2Efficacy & side effects
5(71.4%)
Phase 3Large-scale testing
2(28.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

3

trials recruiting

Total Trials

8

all time

Status Distribution
Active(3)
Completed(2)
Terminated(2)
Other(1)

Detailed Status

Terminated2
Active, not recruiting2
Completed2
unknown1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
3
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 25 (71.4%)
Phase 32 (28.6%)

Trials by Status

terminated225%
unknown113%
active_not_recruiting225%
completed225%
recruiting113%

Recent Activity

3 active trials
Showing 5 of 8
active_not_recruitingphase_2

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

NCT05150652
terminatedphase_2

Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast Cancer

NCT04113863
active_not_recruitingphase_3

Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer

NCT04158362
recruitingphase_3

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)

NCT05512364
unknown

Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia

NCT05800197
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT05150652Phase 2

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

Active Not Recruiting
NCT04113863Phase 2

Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast Cancer

Terminated
NCT04158362Phase 3

Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer

Active Not Recruiting
NCT05512364Phase 3

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)

Recruiting
NCT05800197

Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia

Unknown
NCT03874325Phase 2

Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer

Terminated
NCT03933618Phase 2

Anastrazole and Clomiphene to Evaluate Hypogonadal Symptoms and Erectile Function

Completed
NCT00179517Phase 2

Treatment of Sexual Dysfunction in Hypogonadal Men With Epilepsy With Testosterone and Either Anastrozole or Placebo

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8